

Efficacy on Tocotrienols in the Treatment of non-alcoholic Steatohepatitis: A 10 year Systematic Review

Higinio Mappala*

Jose Reyes Memorial Medical Center, Manila, Philippines

ABSTRACT

Non-alcoholic fatty liver disease (NAFLD) is one of the most common forms of chronic liver disease which may progress to non-alcoholic steatohepatitis (NASH). Currently there are no therapeutic strategies for such disease. Only lifestyle modification through diet and exercise were proven to afford some benefit in patients with NAFLD. No pharmacologic agents have so far been approved for the treatment of NAFLD or NASH. Therefore, most clinical efforts have been directed at treating the components of metabolic syndrome, namely obesity, diabetes, hypertension and dyslipidemias. Other interventions are directed at specific pathways potentially involved in the pathogenesis of NAFLD, such as insulin resistance, oxidative stress, proinflammatory cytokines, apoptosis, bacterial overgrowth, and angiotensin pathway. Objective: This lecture aims to show the potential of Tocotrienols as a promising therapeutic option for NAFLD. Method: This is a 10-year Systematic Review of randomized controlled trials on the effects of Tocotrienols on Non-Alcoholic Fatty Liver Disease. (NAFLD). Conclusion: Tocotrienols may yet prove to be an effective treatment for Non-Alcoholic Fatty Liver Disease.

Keywords: Tocotrienols

Biography:

Higinio T. Mappala is a Full-time Medical Specialist IV and Administrator at the Jose Reyes Memorial Medical Center, Manila, Philippines, A Board-certified Internist, Gastroenterologist, Endoscopist, Clinical Nutritionist and Clinical Toxicologist; has served as a University Professor and Dean of 2 Medical Schools; a highly-regarded Researcher, with more than 70 scientific papers, and more than 30 international publications. A former Board Director of the Philippine Societies of Gastroenterology and Digestive Endoscopy; Editorial Board member, American Journal of Biomedical Science and Research; Online Researcher of McMaster, Canada since 2006; Awardee, World's Leading Physicians in Gastroenterology-2012 and a nominee as one of the Top 100 Leading Physicians 2018 by the Cambridge Biographical Institute. He has been a focused lecturer on NAFLD in local and international conventions for more than 10 years, with 18 invites as Keynote Speaker in 2018, 51 invites in 2019 and 6 advanced invites for 2020 as of this date (Figure 1).

Speaker Publications:

"The Efficacy of Tocotrienols in the Treatment of Non-alcoholic Steatohepatitis: A 10- year Systematic Review".

5th International Conference on Digestive and Metabolic Diseases;



Figure 1: Jose Reyes Memorial Medical Center, Manila, Philippines.

Webinar - November 24, 2020.

Abstract Citation:

Higinio Mappala, The Efficacy of Tocotrienols in the Treatment of Non-alcoholic Steatohepatitis: A 10- year Systematic Review, Digestive Diseases 2020, 5th International Conference on Digestive and Metabolic Diseases; Webinar - November 24, 2020

(<https://digestivediseases.conferenceseries.com/abstract/2020/the-efficacy-of-tocotrienols-in-the-treatment-of-non-alcoholic-steatohepatitis-a-10-year-systematic-review>)

Correspondence to: Higinio Mappala, Department of Internal Medicine, Jose Reyes Memorial Medical Center, Manila, Philippines, Tel: +63 2 8711 9491; Email: genemapmd@yahoo.com

Received: February 16, 2021, **Accepted:** February 18, 2021, **Published:** February 20, 2021

Citation: Mappala H (2021) Efficacy on Tocotrienols in the Treatment of non-alcoholic Steatohepatitis: A 10 year Systematic Review. J Diabetes Metab 12:e103.

Copyright: © 2021 Mappala H. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.